TOR2A Antibody

What is TOR2A and what biological functions does it have?

TOR2A (Torsin family 2 member A), also known as TORP1, belongs to the AAA family of adenosine triphosphatases with similarity to Clp proteases and heat shock proteins . Through alternative splicing and RNA rearrangement, the TOR2A gene produces salusin-α and salusin-β, which are vascular active peptides found in human plasma and urine .

Salusin-β is particularly important in cardiovascular research as it is:

• More abundantly expressed in organs and tissues including heart, brain, kidneys, and especially blood vessels compared to salusin-α

• Implicated in various diseases including atherosclerosis, hypertension, diabetes, and metabolic syndrome

• Involved in regulating proliferation, migration, fibrosis, and calcification of vascular smooth muscle cells (VSMCs)

• A potent hypotensive peptide that may function as endocrine and/or paracrine factors capable of increasing intracellular calcium concentrations and inducing cell mitogenesis

What applications are TOR2A antibodies suitable for in research?

Based on validated research applications, TOR2A antibodies are suitable for:

It is important to note that antibody performance is sample-dependent, and optimization is necessary for each experimental system .

How should I validate TOR2A antibody specificity for my research?

A methodological approach to validating TOR2A antibody specificity includes:

• Positive control verification: Use tissues known to express TOR2A, such as mouse brain or liver tissue for Western blot applications .

• Knockout/knockdown validation: The most rigorous validation involves comparing antibody reactivity between wild-type samples and those where TOR2A has been knocked out or knocked down. Research has established cell lines with TOR2A knockout that can serve as negative controls .

• Molecular weight confirmation: Verify that the detected protein is at the expected molecular weight (40-45 kDa observed, though calculated MW is 36 kDa) .

• Cross-reactivity assessment: Many TOR2A antibodies show cross-reactivity across species (human, mouse, rat, etc.). Confirm the specific reactivity profile needed for your research system .

• Peptide competition assay: If available, use a blocking peptide to confirm signal specificity.

What are the optimal protocols for using TOR2A antibodies in Western blot analysis?

Recommended Western Blot Protocol for TOR2A Detection:

• Sample preparation:

  • For tissue samples: Homogenize in RIPA buffer with protease inhibitors

  • For cell samples: Lyse directly in sample buffer or RIPA buffer

• Protein loading:

  • Load 20-50 μg of total protein per lane

  • Include positive controls (mouse brain or liver tissue)

• Gel electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels

  • Transfer to PVDF membrane (preferred over nitrocellulose)

• Antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Primary antibody: Dilute at 1:500-1:1000 in blocking buffer

  • Incubate overnight at 4°C

  • Secondary antibody: HRP-conjugated anti-rabbit IgG (1:5000-1:10000)

  • Incubate for 1 hour at room temperature

• Detection:

  • Visualize using ECL substrate

  • Expected band: 40-45 kDa

• Controls and validation:

  • Include positive control tissue (mouse brain/liver)

  • Consider including TOR2A knockdown/knockout samples if available

How can I differentiate between detection of salusin-α and salusin-β when using TOR2A antibodies?

This represents a significant challenge in TOR2A research as both salusin-α and salusin-β are products of the same gene:

• Antibody selection strategy:

  • Use antibodies raised against specific epitopes unique to each peptide

  • Verify with the manufacturer which region of TOR2A the antibody recognizes

• Molecular weight differentiation:

  • Full-length TOR2A protein: 40-45 kDa

  • Salusin-α: 5.5 kDa

  • Salusin-β: 4.9 kDa

  • Use appropriate gel percentage (15-20%) for resolving these smaller peptides

• Separation techniques:

  • Consider immunoprecipitation with specific antibodies before analysis

  • Use functional assays that distinguish between the different biological activities of salusin-α versus salusin-β

• Validation approach:

  • Verify specificity using synthetic salusin peptides as positive controls

  • Use recombinant expression systems expressing only one isoform

  • Consider knockdown approaches targeting specific isoforms

What fixation and immunostaining protocols yield optimal results for TOR2A detection in tissue sections?

Recommended Immunohistochemistry Protocol:

• Tissue preparation:

  • Formalin-fixed paraffin-embedded (FFPE) sections (4-6 μm thickness)

  • Fresh-frozen sections may provide better epitope preservation

• Antigen retrieval (critical step):

  • Primary recommendation: TE buffer pH 9.0 (optimal for most TOR2A antibodies)

  • Alternative: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval (pressure cooker or microwave method)

• Blocking and antibody incubation:

  • Block with 5-10% normal serum in PBS

  • Primary antibody dilution: 1:50-1:500 depending on specific antibody

  • Incubate overnight at 4°C or 2 hours at room temperature

• Detection system:

  • Use polymer-based detection systems for higher sensitivity

  • Counterstain with hematoxylin for nuclei visualization

• Controls:

  • Include tissue known to express TOR2A (e.g., stomach tissue)

  • Include a negative control (omitting primary antibody)

  • If possible, include tissue from TOR2A knockout models

How can TOR2A antibodies be utilized to study the role of salusin-β in pulmonary hypertension?

Research has demonstrated that salusin-β promotes pulmonary hypertension through multiple mechanisms. Here's a methodological approach using TOR2A antibodies:

• Expression analysis in disease models:

  • Use Western blot with TOR2A antibodies to quantify salusin-β levels in pulmonary artery tissue from control vs. monocrotaline (MCT)-induced pulmonary hypertension rat models

  • Compare salusin-β expressions in pulmonary arterial smooth muscle cells (PASMCs) isolated from control and pulmonary hypertension rats

• Mechanistic studies:

  • Use immunofluorescence to visualize salusin-β localization in affected tissues

  • Combine with markers for proliferation (Ki67), fibrosis (collagen), and calcification

• Intervention experimental design:

  • Implement knockdown experiments using salusin-β-shRNA via tail vein injection

  • Measure outcomes including:

    • Right ventricular systolic pressure (RVSP)

    • Vascular relaxation (using sodium nitroprusside or acetylcholine)

    • Vascular remodeling parameters

    • ROS production levels

• Quantification methods:

  • Use densitometry for Western blot quantification

  • Implement morphometric analysis for vascular wall thickness

  • Assess collagen content as shown in Table 3 :

What are the recommended approaches for studying the relationship between TOR2A/salusin-β and oxidative stress?

Research has established that salusin-β stimulates NAD(P)H oxidase-derived reactive oxygen species (ROS) production. A methodological approach includes:

• ROS measurement techniques:

  • Use fluorescent probes (e.g., DCFH-DA) to measure intracellular ROS levels in cell culture

  • Quantify ROS and MDA levels in cardiac/vascular tissues

  • Implement SOD activity assays to evaluate antioxidant capacity

• Visualization methods:

  • Use fluorescence microscopy with specific ROS indicators

  • Implement 8-OHdG immunostaining as a marker of oxidative DNA damage

• Experimental design for mechanism studies:

  • Compare ROS levels between:

    • Control tissues/cells

    • Tissues/cells with TOR2A/salusin-β overexpression

    • Tissues/cells with TOR2A/salusin-β knockdown

• Data analysis approach:

  • Quantify fluorescence intensity

  • Normalize to appropriate controls

  • Perform statistical analysis to establish significance of differences

The data from a representative study showed that TOR2A knockdown significantly reduced oxidative stress markers in cardiac tissues, suggesting therapeutic potential for targeting this pathway .

How should researchers design experiments to investigate TOR2A's role in vascular remodeling?

A comprehensive experimental approach should include:

• In vivo models:

  • Utilize the monocrotaline (MCT)-induced pulmonary hypertension rat model

  • Implement angiotensin II-induced cardiac hypertrophy models

  • Design intervention studies using:

    • Viral vectors for TOR2A/salusin-β knockdown

    • Viral vectors for TOR2A/salusin-β overexpression

• Functional measurements:

  • Assess vascular contractility using high K+ solution

  • Evaluate endothelium-dependent relaxation using acetylcholine (ACh)

  • Measure endothelium-independent relaxation using sodium nitroprusside (SNP)

  • Quantify results using parameters from Table 2 :

• Morphological analysis:

  • Implement histological staining for vascular wall thickness

  • Use specific stains for collagen deposition and calcification

  • Quantify cardiomyocyte area in hypertrophy models

• Molecular analysis:

  • Measure expression of genes involved in hypertrophy (ANP, BNP, β-MHC)

  • Quantify fibrosis markers (Collagen I, Collagen III, TGF-β, CTGF)

  • Assess calcification markers

How can I troubleshoot inconsistent results when using TOR2A antibodies in different experimental systems?

Researchers frequently encounter variability when working with TOR2A antibodies. A systematic troubleshooting approach includes:

• Antibody validation concerns:

  • Verify antibody lot consistency with the manufacturer

  • Confirm the antibody recognizes the intended epitope across species

  • Consider using multiple antibodies targeting different epitopes

• Sample preparation variables:

  • For Western blot: Compare different lysis buffers and protein extraction methods

  • For IHC/IF: Test different fixation methods and antigen retrieval protocols

  • Standardize sample handling procedures

• Isoform detection challenges:

  • TOR2A gene produces multiple protein products through alternative splicing

  • Confirm which specific isoform(s) your antibody detects

  • Be aware that LAP1 has multiple isoforms (LAP1B and LAP1C) that may complicate interpretation

• Technical optimization strategies:

  • For Western blot: Test gradient dilutions of primary antibody (1:500-1:1000)

  • For IHC: Compare TE buffer pH 9.0 versus citrate buffer pH 6.0 for antigen retrieval

  • For IF/ICC: Try different fixation methods (paraformaldehyde vs. methanol)

• Control implementation:

  • Use genetically modified systems (knockout/knockdown) as definitive controls

  • Include tissue with known expression pattern (e.g., mouse brain/liver)

What is known about the differential functions of TOR2A compared to other Torsin family members (TorA, TorB, Tor3A)?

Understanding the functional differences between Torsin family members is crucial for experimental design:

• Functional distinction through cofactor interaction:

  • TorA and TorB ATPase activities are activated by both LAP1 and LULL1

  • Tor3A is activated only by LULL1

  • Tor2A's ATPase activity is not activated by either LAP1 or LULL1

• Functional redundancy observations:

  • Research demonstrates a direct correlation between the number of inactivated Torsin alleles and nuclear envelope (NE) blebbing phenotype

  • Deletion of Tor2A in a TorA/B/3A-deficient background results in increased bleb formation

• Experimental approach to study functional differences:

  • Generate cell lines with individual and combined Torsin knockouts

  • Quantify phenotypic effects using nuclear envelope morphology as a readout

  • Measure blebbing frequency (blebs/30 μm of NE)

• Quantitative phenotypic data:

  • TorA/B double KO: ~0.6 blebs/30 μm of NE

  • TorA/B/3A triple KO: ~3.3 blebs/30 μm of NE

  • TorA/B/3A/2A quadruple KO: ~5.9 blebs/30 μm of NE

How might researchers effectively target salusin-β for therapeutic intervention in cardiovascular and pulmonary diseases?

Based on current research findings, several therapeutic approaches could be considered:

• Gene therapy approaches:

  • TOR2A knockdown via shRNA delivery has shown efficacy in alleviating:

    • Cardiac hypertrophy

    • Cardiac fibrosis

    • Oxidative stress

    • Excess autophagy in hypertrophic cardiomyopathy models

• Targeting specific mechanisms:

  • NAD(P)H oxidase inhibition to block ROS production stimulated by salusin-β

  • Autophagy modulation to counteract salusin-β-induced cardiac effects

• Experimental design for therapeutic validation:

  • Implement prevention vs. reversal experimental paradigms

  • Compare local vs. systemic delivery methods

  • Evaluate timing of intervention relative to disease progression

• Outcome measurements:

  • Functional metrics (vascular relaxation, RVSP, cardiac function)

  • Molecular markers (oxidative stress, fibrosis markers)

  • Histopathological analysis (vascular remodeling, cardiac hypertrophy)

What controls should be implemented when using TOR2A antibodies for advanced research applications?

Proper experimental controls are essential for rigorous TOR2A antibody-based research:

• Positive controls:

  • Tissue/cells known to express TOR2A (mouse brain/liver tissue)

  • Recombinant TOR2A protein

• Negative controls:

  • TOR2A knockout/knockdown models or cells

  • Primary antibody omission control for IHC/IF

  • Isotype control antibody

• Specificity controls:

  • Peptide competition assay using the immunogen peptide

  • Comparison of multiple antibodies targeting different TOR2A epitopes

• Loading/technical controls:

  • For Western blot: Housekeeping proteins (β-actin, GAPDH)

  • For IHC: Adjacent section controls

  • For ICC/IF: Nuclear counterstain to verify cell integrity

• Treatment validation controls:

  • Vehicle-only controls for drug treatments

  • Empty vector controls for overexpression/knockdown studies

The implementation of these controls ensures that observed effects are specifically related to TOR2A/salusin-β rather than technical artifacts or non-specific antibody binding.

What are the primary technical limitations of current TOR2A antibodies for research applications?

Researchers should be aware of several technical limitations:

• Isoform specificity challenges:

  • Most commercial antibodies may not distinguish between salusin-α and salusin-β

  • Limited ability to detect specific post-translational modifications

• Cross-reactivity considerations:

  • Variable cross-reactivity across species (human, mouse, rat)

  • Potential cross-reactivity with other Torsin family members

• Application restrictions:

  • Performance varies across applications (WB, IHC, IF)

  • Antibody may perform well in Western blot but poorly in IHC or vice versa

• Technical variability:

  • Lot-to-lot variability between antibody preparations

  • Optimization required for each new experimental system

  • Different fixation methods may affect epitope accessibility

• Validation challenges:

  • Limited availability of knockout controls for antibody validation

  • Inconsistent validation standards across manufacturers